In my post of October 3rd, 2013, I had already pointed out that the American FDA had approved the new antidepressant vortioxetine. On December 18th, 2013, the European agency EMA followed this decision and approved the drug for use in the EU. I have already published a detailed substance characteristics. It is expected that vortioxetine will be available in the second quarter of 2014. The trade name is Brintellix®.
The pricing will be very interesting. Meanwhile, almost all antidepressants are available as generics. The manufacturers of Brintellix®, Lundbeck and Takeda, can initially set the price for their product freely. This applies to the first twelve months. Very soon, however, the Institute for Quality and Cost Effectiveness in Health Care (IQWiG) will assess whether there is an additional benefit of vortioxetine compared to the available – very cheap – compounds. Thus, in 2015 it will turn out, whether Lundbeck and Takeda can achieve the desired price for their product.
This post is also available in: German